453 related articles for article (PubMed ID: 27411590)
21. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
22. Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
Yamato M; Sakai Y; Mochida H; Kawaguchi K; Takamura M; Usui S; Seki A; Mizukoshi E; Yamashita T; Yamashita T; Ishida K; Nasti A; Tuyen HTB; Komura T; Yoshida K; Wada T; Honda M; Kaneko S
J Gastroenterol Hepatol; 2019 Aug; 34(8):1432-1440. PubMed ID: 30828861
[TBL] [Abstract][Full Text] [Related]
23. Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma.
Márquez-Quiroga LV; Arellanes-Robledo J; Vásquez-Garzón VR; Villa-Treviño S; Muriel P
Biochem Pharmacol; 2022 Jan; 195():114845. PubMed ID: 34801522
[TBL] [Abstract][Full Text] [Related]
24. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
Koo SY; Park EJ; Lee CW
Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
[TBL] [Abstract][Full Text] [Related]
25. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
26. P(URI)fying Novel Drivers of NASH and HCC: A Feedforward Loop of IL17A via White Adipose Tissue.
Weber A; Heikenwalder M
Cancer Cell; 2016 Jul; 30(1):15-17. PubMed ID: 27411585
[TBL] [Abstract][Full Text] [Related]
27. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
28. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
[TBL] [Abstract][Full Text] [Related]
29. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.
Liang JQ; Teoh N; Xu L; Pok S; Li X; Chu ESH; Chiu J; Dong L; Arfianti E; Haigh WG; Yeh MM; Ioannou GN; Sung JJY; Farrell G; Yu J
Nat Commun; 2018 Oct; 9(1):4490. PubMed ID: 30367044
[TBL] [Abstract][Full Text] [Related]
30. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma.
Fujii M; Shibazaki Y; Wakamatsu K; Honda Y; Kawauchi Y; Suzuki K; Arumugam S; Watanabe K; Ichida T; Asakura H; Yoneyama H
Med Mol Morphol; 2013 Sep; 46(3):141-52. PubMed ID: 23430399
[TBL] [Abstract][Full Text] [Related]
31. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-17 in Liver Disease Pathogenesis.
Li N; Yamamoto G; Fuji H; Kisseleva T
Semin Liver Dis; 2021 Nov; 41(4):507-515. PubMed ID: 34130335
[TBL] [Abstract][Full Text] [Related]
33. Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.
Allard B; Jacoberger-Foissac C; Cousineau I; Bareche Y; Buisseret L; Chrobak P; Allard D; Pommey S; Ah-Pine F; Duquenne S; Picard F; Stagg J
Cell Rep Med; 2023 Sep; 4(9):101188. PubMed ID: 37729873
[TBL] [Abstract][Full Text] [Related]
34. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation.
Tan Z; Qian X; Jiang R; Liu Q; Wang Y; Chen C; Wang X; Ryffel B; Sun B
J Immunol; 2013 Aug; 191(4):1835-44. PubMed ID: 23842754
[TBL] [Abstract][Full Text] [Related]
35. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.
Ganz M; Csak T; Szabo G
World J Gastroenterol; 2014 Jul; 20(26):8525-34. PubMed ID: 25024607
[TBL] [Abstract][Full Text] [Related]
36. Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Mazzoccoli G; Miele L; Oben J; Grieco A; Vinciguerra M
Curr Drug Targets; 2016; 17(7):783-99. PubMed ID: 26648069
[TBL] [Abstract][Full Text] [Related]
37. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
38. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
39. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
40. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
